KROS FY 2022 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$115M

Net Income

-$105M

EPS (Diluted)

$-4.15

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$71M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$307M

Total Liabilities

$29M

Stockholders' Equity

$277M

Cash & Equivalents

$279M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$20M	-100.0%
Gross Profit	$0	$20M	-100.0%
Operating Income	-$115M	-$56M	-103.6%
Net Income	-$105M	-$59M	-78.2%